Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Effectiveness of Buprenorphine/Naloxone in Reducing Intravenous Buprenorphine Misuse in France ("RIME")

This study has been completed.
Information provided by (Responsible Party):
Reckitt Benckiser Pharmaceuticals Inc. Identifier:
First received: August 5, 2009
Last updated: November 28, 2012
Last verified: January 2010

Patients who admit to using buprenorphine by the intravenous route will be randomized to either Subutex or Suboxone and be followed up for 3 months to determine if there is less injection with Suboxone than with Subutex based primarily on patient diaries.

Patients randomized to Suboxone may continue to receive the product for a further 9 months at their request and will be monitored at 3 month intervals.

Patients will receive a payment for the inconvenience of keeping a daily diary and to cover their travel expenses.

Condition Intervention Phase
Opioid Dependency
Drug: Buprenorphine (Subutex)
Drug: Buprenorphine/naloxone (Suboxone)
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Multicentre, Randomised, Open-label, Active-controlled Trial of the Effectiveness of Buprenorphine/Naloxone in Reducing Intravenous Buprenorphine Misuse in France

Resource links provided by NLM:

Further study details as provided by Reckitt Benckiser Pharmaceuticals Inc.:

Primary Outcome Measures:
  • number of study drug injections per week [ Time Frame: 1 week ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Addiction severity [ Time Frame: 3 months ] [ Designated as safety issue: No ]
  • Withdrawal severity [ Time Frame: 1 month ] [ Designated as safety issue: No ]

Enrollment: 270
Study Start Date: August 2009
Study Completion Date: May 2011
Primary Completion Date: May 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Subutex Drug: Buprenorphine (Subutex)
Sublingual tablet
Other Name: Subutex
Experimental: Suboxone Drug: Buprenorphine/naloxone (Suboxone)
Sublingual tablet
Other Name: Suboxone


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male or female opioid-dependent outpatient aged 18 years or older,
  2. Women of childbearing potential must have a negative urine pregnancy test result at the Inclusion Visit (test under supervision of the investigator or designee),
  3. Women of childbearing potential must use an effective birth control method. Women of non-childbearing potential must be postmenopausal or must be surgically sterile (hysterectomy and/or bilateral oophorectomy),
  4. On buprenorphine (Subutex® or generic buprenorphine) maintenance therapy at a minimum daily dose of 2 mg for at least 3 months prior to inclusion,
  5. Declaring buprenorphine intravenous misuse at least four times/week and showing needle marks,
  6. Willing to stop or reduce buprenorphine intravenous misuse,
  7. Having received oral and written information about the trial, and provided written informed consent prior to admission to this trial.

Exclusion Criteria:

  1. Pregnancy or breast-feeding,
  2. Contraindication or history of hypersensitivity to buprenorphine, naloxone or to any excipient of Suboxone® or Subutex®,
  3. Any medical or psychiatric condition which in the opinion of the investigator would make participation difficult or unsafe,
  4. Participating in another trial,
  5. Patients in the exclusion period of the "Fichier National des personnes qui se prêtent à des recherches biomédicales" (National Index of persons participating in biomedical researches, or National Index of volunteers).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00955162

Csst Antibes
Antibes, France
Hopital Paul Guiraud
Bagneux, France
Cssa Bizia
Bayonne, France
Centre Carreire , CH Charles Perrens
Bordeaux, France
CHU de Clermont-Ferrand, Centre Méthadone
Clermont-Ferrand, France
Service d'addictologie, Hopital de Dole
Dole, France
Le Havre, France
CSST Le Cèdre Bleu
Lille, France
Centre Hospitalier Esquirol - Intersecteur, Regional Soins en Addictologie
Limoges, France
Centre Baudelaire
Metz, France
Csst de Montauban
Montauban, France
CSST Centre Hospitalier
Nice, France
CSST Logos
Nimes, France
Hôpital Caremeau
Nimes, France
Hôpital Saint Anne
Paris, France
Csst Espace Murger
Paris, France
Centre L'Envol (Csst)
Rennes, France
Centre Baudelaire
Thionville, France
Hopital Joseph Ducuing
Toulouse, France
CSST Centre Port Bretagne CH Charles Perrens
Tours, France
Sponsors and Collaborators
Reckitt Benckiser Pharmaceuticals Inc.
Principal Investigator: Didier TOUZEAU, MD Hôpital Paul Guiraud, Bagneux
  More Information

No publications provided

Responsible Party: Reckitt Benckiser Pharmaceuticals Inc. Identifier: NCT00955162     History of Changes
Other Study ID Numbers: BU0902
Study First Received: August 5, 2009
Last Updated: November 28, 2012
Health Authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Keywords provided by Reckitt Benckiser Pharmaceuticals Inc.:
Substance Abuse, Intravenous

Additional relevant MeSH terms:
Analgesics, Opioid
Central Nervous System Agents
Central Nervous System Depressants
Narcotic Antagonists
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses processed this record on November 25, 2014